New Delhi: The Russian government contacted the Indian dispensation, a collaboration on the Russian vaccine Covid-19, Sputnik V, and also expressed its readiness to the percentage data, as thePrint learned.
This comes at a time when the Indian Embassy in Moscow is collaborating with the Gamaleya National Center for Epidemiology and Microbiology, which developed the vaccine, to download knowledge on the protection and effectiveness of vaccine trials.
Government resources told ThePrint that Russia’s ambassador to India, Nikolay Kudashev, had officially communicated with the Indian government’s most sensible clinical adviser, Professor K.VijayRaghavan, the secretary of the DBT (Department of Biotechnology), Ranu Swarup, and the secretary of the Department of Health Research, Dr. Balram Bhargava, who is also the director general of the Medical Research Council of India.
“Russia’s ambassador to India collaborates with the offices of the Chief Scientific Adviser and the Secretaries of the Department of Health Research and the Department of Biotechnology. The Russian government needs to work with India on the vaccine. They have also actively shared a great deal of data and knowledge about Sputnik V, but the maximum knowledge on protection and power for which we are has not yet been shared,” said one Ministry of Health official.
“Our embassy in Moscow is also there to gain the knowledge and is in contact with the Gamaleya Institute,” he added.
However, there is still no call for trials in India and the central government, open to the idea, is proceeding cautiously until very important knowledge is available.
“Someone has to ask for a trial in India, whether the institute or the company does. That didn’t happen,” the official added.
Read also: Sputnik launch in Russia increases risks in Covid vaccine fever
Sputnik V is a vector-based adenovirus vaccine that was registered through the Russian Ministry of Health on August 11. It is the world’s first covid-19 vaccine, but knowledge of the vaccine has not yet been shared with other countries or with the World Health Organization (WHO).
The WHO panoramic document for Covid vaccines still lists candidate Gamaleya as in test phase I, while in Russia, arrangements are being made for large-scale vaccine production and management.
President Vladimir Putin’s daughter was one of the first to get the vaccine even when lack of knowledge led to global cynicism.
Among the cynics is Dr. Anthony Fauci, director of the U.S. National Center for Allergy and Infectious Diseases, who reportedly said: “I hope the Russians have definitively shown that the vaccine is safe and effective. I seriously doubt they did.”
Information on clinical trials available to the public to date on Sputnik V can be found on its website.
“Phase 1 and 2 clinical trials of the vaccine ended on August 1, 2020. All volunteers feel good, no adverse or unforeseen effects have been observed. The vaccine induced a strong cellular immune reaction and antibodies. He is not an ongoing single player Inflamed clinical trials with Covid-19 after being administered with the vaccine.
‘The maximum efficacy of the vaccine has been demonstrated through high-precision testing for antibodies in the blood serum of volunteers (including research of antibodies neutralizing the coronavirus), as well as the ability of volunteers’ immune cells to activate in reaction to the peak of the coronavirus S protein, which indicates the formation of antibodies and a cellular immune reaction” Array said.
“Post-registration clinical trials involving more than 40,000 people in Russia will be introduced in one week from 24 August. Several countries, such as the United Arab Emirates, Saudi Arabia, the Philippines and perhaps India or Brazil will enroll in Sputnik V Clinical Trials at the local level.”
The plan is to increase vaccine production to two hundred million doses by the end of 2020, adding 30 million doses in Russia.
He also asserts that “at least 20 countries have expressed interest in obtaining Sputnik V, adding the United Arab Emirates, Saudi Arabia, Indonesia, the Philippines, Brazil, Mexico and India”.
Read also: The government has won any application for phase 3 trials of the Russian Covid Sputnik V vaccine in India
Why the media is in crisis and how to fix it
You’re reading this because you’re a quality, intelligent, objective journalist. Thank you for your time and confidence.
He also knows that the media is facing an unprecedented crisis. You’ll most likely also hear about sudden layoffs and pay cuts in the industry. There are many reasons why the media economy is broken. But the main challenge is that the other right people still don’t pay enough for smart journalism.
We have a newsroom full of talented young reporters. We also have the most powerful data editing and verification team in the country, news photographers and video professionals. We are building India’s most ambitious and dynamic data platform. And I just turned three.
At ThePrint, we invest in quality news. We pay them fairly. As you may have noticed, we are not reluctant to spend whatever it takes to make sure our hounds get to where the story is.
This comes at an abundant cost. So that we can continue to offer quality journalism, we want readers like you to pay.
If you think we deserve your help, sign up for us in this effort for fair, free, courageous and wonderful journalism. Click on the link below. Your help will describe the long-term of ThePrint.
Support our journalism